RUNX1T1 and neoplasm: The Th-MYCN+/−; Runx1t1+/+ mice displayed 9.9% tumor incidence (18/181), as compared to 0.87% (3/343) in Th-MYCN+/−; Runx1t1+/− mice (Supplementary Fig. 1e).